These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16777694)

  • 1. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
    Schlesselman JJ; Reis IM
    Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Admissible two-stage designs for phase II cancer clinical trials.
    Jung SH; Lee T; Kim K; George SL
    Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
    Sambucini V
    Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian two-stage designs for phase II clinical trials.
    Tan SB; Machin D
    Stat Med; 2006 Oct; 25(19):3407-8. PubMed ID: 16847890
    [No Abstract]   [Full Text] [Related]  

  • 10. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative designs of phase II trials considering response and toxicity.
    Jin H
    Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balanced two-stage designs for phase II clinical trials.
    Ye F; Shyr Y
    Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.
    Zohar S; Teramukai S; Zhou Y
    Contemp Clin Trials; 2008 Jul; 29(4):608-16. PubMed ID: 18201945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How large should a phase II trial of a new drug be?
    Simon R
    Cancer Treat Rep; 1987 Nov; 71(11):1079-85. PubMed ID: 3315196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
    Sposto R; Gaynon PS
    Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
    Michaelis LC; Ratain MJ
    Clin Cancer Res; 2007 Apr; 13(8):2400-5. PubMed ID: 17438099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.